Roche Spends $451 Million to Acquire Inflazome's NLRP3 Program

Roche Spends $451 Million to Acquire Inflazome’s NLRP3 Program

The deal will provide the pharma giant with a unique new platform for tackling autoimmune diseases.

Read More…

You May Also Like